| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Ferroptosis-IN-24 (compound D12) (6.25-12.5 μM; 24 h) effectively inhibited RSL3-induced ferroptosis in PC12 cells with an EC50 value of 39.7 nM; cell viability increased to 90.7% and 96.5% at concentrations of 6.25 μM and 12.5 μM, respectively [1]. Ferroptosis-IN-24 (24 h) inhibited Erastin-induced ferroptosis in PC12 cells with an EC50 value of 410.4 nM [1]. Ferroptosis-IN-24 (1 μM; 8 h) effectively reduced RSL3-induced intracellular ROS accumulation in PC12 cells [1]. Ferroptosis-IN-24 (1 μM; 8 h) effectively inhibited RSL3-induced lipid peroxidation in PC12 cells [1]. Ferroptosis-IN-24 (1 μM; 6 h) can reverse the downregulation of GPX4 and Nrf2 protein expression induced by RSL3 in PC12 cells[1]. Ferroptosis-IN-24 (1 μM) can reduce the stress-induced overexpression of GPX4, Nrf2, HMOX1 and NQO1 mRNA in RSL3-treated PC12 cells, indicating that it alleviates upstream oxidative stress rather than directly activating the Nrf2 pathway[1].
|
|---|---|
| ln Vivo |
Ferroptosis-IN-24 (10-20 mg/kg; intraperitoneal injection; single pretreatment) dose-dependently reduced liver necrosis in a mouse model of acetaminophen-induced acute liver injury, restored liver enzyme and antioxidant levels, and improved histological appearance [1]. Ferroptosis-IN-24 (10 mg/kg; intravenous injection; single pretreatment) reduced cerebral infarction volume and improved neurological deficits in a rat model of MCAO-induced cerebral ischemia-reperfusion injury [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: PC12 cells (RSL3-induced ferroptosis) Tested Concentrations: 6.25 μM; 12.5 μM Incubation Duration: 24 hours Experimental Results: Under RSL3-induced ferroptosis conditions, the viability of PC12 cells increased to 90.7% at a concentration of 6.25 μM. Under RSL3-induced ferroptosis conditions, the viability of PC12 cells increased to 96.5% at a concentration of 12.5 μM. Western Blot Analysis [1] Cell Types: PC12 cells (RSL3 treatment) Tested Concentrations: 1 μM Incubation Duration: 6 hours Experimental Results: The downregulation of GPX4 protein level in RSL3-induced PC12 cells was reversed, restoring its expression to near control levels. The downregulation of Nrf2 protein level in RSL3-induced PC12 cells was reversed, restoring its expression to near control levels. |
| Animal Protocol |
Animal/Disease Models:C57BL/6 (male, acetaminophen-induced acute liver injury model) [1]
Doses: 10 mg/kg; 20 mg/kg Route of Administration: Intraperitoneal injection; Single pretreatment (1 hour before acetaminophen challenge) Experimental Results: Liver necrosis decreased in a dose-dependent manner, with liver histology approaching normal at 20 mg/kg. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels decreased. Hepatic glutathione (GSH) levels recovered. Malondialdehyde (MDA) levels decreased. Animal/Disease Models:SD (male, MCAO-induced cerebral ischemia-reperfusion injury model) [1] Doses: 10 mg/kg Route of Administration: Intravenous injection; single pretreatment (1 hour before MCAO, followed by 24 hours of reperfusion) Experimental Results: Reduced infarct volume. Improved neurological deficits. |
| References |
| Molecular Formula |
C18H15NO3
|
|---|---|
| Molecular Weight |
293.32
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=C(C1=CC(OC(C)=O)=C2N1C=CC=C2)C3=CC=CC=C3C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4092 mL | 17.0462 mL | 34.0925 mL | |
| 5 mM | 0.6818 mL | 3.4092 mL | 6.8185 mL | |
| 10 mM | 0.3409 mL | 1.7046 mL | 3.4092 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
